In the past week, KRON stock has gone down by -0.58%, with a monthly gain of 28.84% and a quarterly plunge of -3.13%. The volatility ratio for the week is 1.42%, and the volatility levels for the last 30 days are 5.84% for Kronos Bio Inc The simple moving average for the past 20 days is 11.44% for KRON’s stock, with a -4.59% simple moving average for the past 200 days.
Is It Worth Investing in Kronos Bio Inc (NASDAQ: KRON) Right Now?
The stock has a 36-month beta value of 1.64. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KRON is 39.45M, and at present, short sellers hold a 1.91% of that float. On June 20, 2025, the average trading volume of KRON was 787.09K shares.
KRON) stock’s latest price update
The stock price of Kronos Bio Inc (NASDAQ: KRON) has dropped by -2.02 compared to previous close of 0.88. Despite this, the company has seen a fall of -0.58% in its stock price over the last five trading days. businesswire.com reported 2025-05-04 that NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kronos Bio, Inc. (NasdaqGS: KRON) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Kronos will receive $0.57 in cash per share plus one non-tradeable contingent value right. KSF is seeking to determine whether this consideration and the process that le.
Analysts’ Opinion of KRON
Piper Sandler, on the other hand, stated in their research note that they expect to see KRON reach a price target of $1, previously predicting the price at $6. The rating they have provided for KRON stocks is “Neutral” according to the report published on November 14th, 2024.
Berenberg gave a rating of “Buy” to KRON, setting the target price at $12 in the report published on September 14th of the previous year.
KRON Trading at 10.73% from the 50-Day Moving Average
After a stumble in the market that brought KRON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.81% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KRON starting from KNOBELMAN DEBORAH, who sale 24,838 shares at the price of $0.87 back on Jun 05 ’25. After this action, KNOBELMAN DEBORAH now owns 139,422 shares of Kronos Bio Inc, valued at $21,554 using the latest closing price.
BISCHOFBERGER NORBERT W, the PRESIDENT & CEO of Kronos Bio Inc, purchase 410,848 shares at $1.17 during a trade that took place back on Jun 27 ’24, which means that BISCHOFBERGER NORBERT W is holding 10,597,468 shares at $478,843 based on the most recent closing price.
Stock Fundamentals for KRON
Current profitability levels for the company are sitting at:
- -7.65 for the present operating margin
- 1.0 for the gross margin
The net margin for Kronos Bio Inc stands at -7.02. The total capital return value is set at -0.7. Equity return is now at value -59.49, with -44.30 for asset returns.
Based on Kronos Bio Inc (KRON), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -2.26.
Currently, EBITDA for the company is -61.72 million with net debt to EBITDA at 1.37. When we switch over and look at the enterprise to sales, we see a ratio of -1.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.93.
Conclusion
To sum up, Kronos Bio Inc (KRON) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
